CE25-149 - rigorous evaluation of community-delivered short- and long-acting buprenorphine to people who experience homelessness or live at permanent supportive housing sites

The Centers for Disease Control and Prevention (CDC) awarded a $700,000 cooperative agreement to King County, doing business as Public Health-Seattle & King County, on September 30, 2025, to conduct a rigorous evaluation of community-delivered short- and long-acting buprenorphine for people who experience homelessness or live at permanent supportive housing sites.

The award operates under the Injury Prevention and Control Research and State and Community Based Programs (CFDA 93.136), which supports injury and violence prevention and control practices through state and community-based interventions. The period of performance extends from September 30, 2025 through September 29, 2028, with work performed in Washington. The cooperative agreement is a non-competitive continuation vehicle; after the initial budget period, projects may continue subject to satisfactory progress documentation and federal determination that continuation serves the government's interest.

King County is a county government entity providing public health and community services across a population of approximately 2.2 million residents. As the recipient, King County will conduct the evaluation activities directly. The program focuses on treatment outcomes and implementation effectiveness for buprenorphine delivery in community settings serving vulnerable populations experiencing housing instability.